Resverlogix Corp. (RVXCF) Research

Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bromodomain and extra-terminal inhibitor, which is currently undergoing Phase III clinical trials. This investigational treatment aims to address a spectrum of serious ailments, including cardiovascular disease, diabetes mellitus, chronic and end-stage kidney disease, and neurodegenerative disorders. Furthermore, Resverlogix has established a collaboration with Eversana Life Science Services, LLC. This alliance is geared towards supporting the forthcoming commercial introduction of apabetalone as a treatment for COVID-19 in both the United States and Canada. The company's operations are based out of Calgary, Canada.

Market snapshot

Symbol
RVXCF
Price
$0.07
Day change
0.00%
Market cap
$22.4M
P/E ratio
-3.25x
52-week range
0.03-0.21
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Bonus BioGroup Ltd. (BBIXF)
  • Cell Source, Inc. (CLCS)
  • Celyad Oncology S.A. (CLYYF)
  • Charlotte's Web Holdings, Inc. (CWBHF)
  • Evolva Holding S.A. (ELVAF)
  • Finch Therapeutics Group, Inc. (FNCH)
  • MediPharm Labs Corp. (MEDIF)
  • Institute of Biomedical Research Corp. (MRES)

Open Resverlogix Corp. (RVXCF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.